Week 128 Review - Crypto shares perform best and worst

A flat week that's registering as a loss of £123 but that's the difference between cost and value. I banked £496 profit, so really there was a small tick up if you look at just the portfolio value. It is now £363 higher than last week at £74,256 although the buffer between cost and value is down to £2,414.

The worst performer this week was BLU:Blue Star Capital, dropping 10% and now down 41% in the few weeks I have owned it. We'll see later that these types of shares can be a tad volatile though.

MTFB:Motif Bio has rallied recently, but is heading down again now, dropping 9% this week.

RED:RedT Energy is another share that's rallied over the last few weeks and people must be profit taking as this dropped 8%.

No change at all for OPTI:Optibiotix despite yet more great news.

IQE:IQE staged a bit of a recovery, managing to save me from the falls elsewhere by climbing 5% in my SIPP and 17% of purchase price in my ISA. I just wish the shorters would give up and let this settle.

IKA:Ilika has surged recently, climbing 9% this week and only just missing out on Share of the Week. It's still 56% down so a long way to go yet.

Share of the Week is my other crypto-currency company LION:Lionsgold, climbing 13% in my trading account but still 25% down. Yesterday the share price surged 86% but fell 18% today so no chance of reaching my 7p limit sell order. Maybe calling it a giant turkey last week was premature!

Looks pretty flat to me.

The ISA and share portfolios look like this

			Weekly Change
Cash	£10.89		+£0
Portfolio cost	£44,964.39		+£0
Portfolio sell value (bid price - commission)	£45.462.58	(1.1%)	+£270.65
Potential profits	£7,118.52		+£379.63
Yr 3 Dividends	£34.11		+£0
Yr 3 Profit from sales	£1,104.47		+£0
Yr 3 Average monthly cash profit	£202.19	(5.4%)	-£8.79
Total Dividends	£1,213.16		+£0
Total Profit from sales	£7,816.97		+£0
Average monthly cash profit	£301.51	(8.0%)	-£2.37
(Sold stocks profit + Dividends - Fees / Months)

Quite a nice calm week, with the rise in IQE:IQE enough to stifle the losses elsewhere.

Just scraping along the top of the red line - far too close for comfort.

The SIPP looks like this after week 112

			Weekly Change
Cash	£39.01		+£11.32
Portfolio cost	£26,492.59		+£485.56
Portfolio sell value (bid price - commission)	£28,497.03	(7.6%)	-£438.42
Potential profits	£4,010.76		-£501.96
Yr 3 Dividends	£0		+£0
Yr 3 Profit from sales	£496.89		+£496.89
Yr 3 Average monthly cash profit	£228.83	(10.4%)	+£242.21
Total Dividends	£916.10		+£0
Total Profit from sales	£9,422.08		+£496.89
Average monthly cash profit	£389.95	(17.7%)	+£12.37
(Sold stocks profit + Dividends - Fees / Months)

The sale of CAML:Central Asia Metals gave me £496 profit for year 3 and improved my overall average monthly performance by £12.37 a month. The portfolio was pretty flat otherwise, with the profits and sell value dropping by about the same amount as the cost value went up. Cash got another £11 as the limit order came in cheaper than the 65p I set, and you have to quote a number of shares rather than an amount of money. I missed out on another 17 shares because of that!

CAML:Central Asia Metals is now down to 10.1% of my portfolio value, so my plan to implement the 10% rule worked perfectly, up to the point I allowed OPTI:Optibiotix to go to 50.7% of my portfolio value by buying a load more!

Pretty flat here too, but the cost sneaks up a bit more.

Here's the less depressing trading account after week 78

			Weekly Change
Cash	£0.03		+£0
Portfolio cost	£345.65		+£0
Portfolio sell value (bid price - commission)	£257.82	(-25.4%)	+£44.34
Potential profits	£0		+£0
Year 2 Dividends	£0		+£0
Year 2 Profit	-£218.50		+£0
Yr 2 Average monthly cash profit	-£36.42	(-126.4%)	+£1.45
Dividends	£1.15		+£0
Profit from sales	-£241.35		+£0
Average monthly cash profit	-£13.34	(-46.3%)	+£0.18
(Sold stocks profit + Dividends - Fees / Months)

I think LION:Lionsgold is a good trading share, with 86% rises followed by 18% drops. If I was clever I would have bought just before the 86% rise, but although saying I should do it I didn't. I think I may get to sell these sooner than I thought - and next time will be a bit more careful when I buy - wait for the sweet spot!!

Let's hope it lasts

That's it for week 128. When OPTI:Optibiotix released one of the most exciting RNSs yet, absolutely nothing happened to the share price. However, I was able to get my average price down a bit more and topping 50% of my portfolio cost means this is where I definitely stop buying. Honest. This time I really mean it...